- Document Number:
20240360182
- Appl. No:
18/768701
- Application Filed:
July 10, 2024
- نبذة مختصرة :
Provided herein is a nucleic acid comprising consensus amino acid sequence of foot-and-mouth disease FMDV VP1-4 coat proteins of FMDV subtypes A, Asia 1, C, O, SAT1, SAT2, and SAT3 as well as plasmids and vaccines expressing the sequences. Also provided herein is methods for generating an immune response against one or more FMDV subtypes using the vaccine as described above as well as methods for deciphering between vaccinated mammals with the vaccine and those that are infected with FMDV.
- Claim:
1. An isolated nucleic acid comprising a sequence encoding a protein having one or more sequences selected from the group consisting of: one or more of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40 and 42 with or without a leader sequence, complements thereof, immunogenic fragments thereof comprising at least 20 amino acids, variants with 80% or more homology to SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40 and 42, complements thereof, immunogenic fragments thereof comprising at least 20 amino acids, and complements thereof,
- Claim:
2. The nucleic acid of claim 1, wherein the sequence is selected from the group consisting of: SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39 and 41 with or without coding sequence for a leader sequence, complements thereof, fragments thereof encoding at least 20 amino acids, complements thereof, nucleic acid molecules 80% homologous to SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39 and 41, complements thereof, fragments thereof encoding at least 20 amino acids, and complements thereof
- Claim:
3. The nucleic acid of claim 1 comprising a sequence encoding a protein selected from the group consisting of: SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40 and 42 with or without a leader sequence.
- Claim:
4. The nucleic acid of claim 1 comprising a sequence selected from the group consisting of: SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39 and 41.
- Claim:
5. The nucleic acid of any of claims 1-4 wherein the leader sequence is an Ige leader sequence.
- Claim:
6. The nucleic acid of any of claims 1-5 wherein said nucleic acid is a plasmid.
- Claim:
7. The nucleic acid of any of claims 1-6 wherein said nucleic acid is a plasmid that is an expression vector.
- Claim:
8. A vaccine comprising a nucleic acid of any of claims 1-7 and/or one or more proteins selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40 and 42 with or without a leader sequence, complements thereof, immunogenic fragments thereof comprising at least 20 amino acids, variants with 80% or more homology to SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40 and 42, complements thereof, immunogenic fragments thereof comprising at least 20 amino acids, and complements thereof.
- Claim:
9. The vaccine of claim 8 further comprising an adjuvant.
- Claim:
10. The vaccine of claim 8 further comprising an adjuvant is selected from the group consisting of IL-12 and/or IL-15 or a nucleic acid sequence encoding IL-12 and/or IL-15.
- Claim:
11. A compositions comprising one or more proteins selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40 and 42 with or without a leader sequence, complements thereof, immunogenic fragments thereof comprising at least 20 amino acids, variants with 80% or more homology to SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40 and 42, complements thereof, immunogenic fragments thereof comprising at least 20 amino acids, and complements thereof
- Claim:
12. A method of eliciting an immune response against one or more FMDV virus subtypes in a mammal, comprising administering a vaccine according to claim 8.
- Claim:
13. The method of claim 12 wherein the vaccine comprises a nucleic acid molecule, the method comprising the steps of a) administering the nucleic acid molecule to the tissue of the mammal; and b) electroporating cells of the tissue with a pulse of energy at a constant current effective to permit entry of the DNA plasmid into the cells.
- Claim:
14. The method of claim 13 wherein step a) comprises injecting the DNA plasmid vaccine into intradermic, subcutaneous, or muscle tissue.
- Claim:
15. The method of claim 13 or 14 wherein the current is preset for delivering to the tissue and pulse of energy is at a constant current that equals the preset current.
- Claim:
16. The method of any of claims 13-15 wherein the electroporating step further comprises: (a) measuring the impedence in the electroporated cells; (b) adjusting the energy level of the pulse of energy relative to the measured impedance to maintain a constant current in the electroporated cells; wherein the measuring and adjusting steps occur within a lifetime of the pulse of energy.
- Claim:
17. The method of any of claims 13-16 wherein the electroporation step comprise delivering the pulse of energy to a plurality of electrodes according to a pulse sequence pattern that delivers the pulse of energy in a decentralized pattern.
- Claim:
18. The method of any of claims 12-17, wherein the mammal has not been infected with FMDV and the immune response is a protective immune response.
- Claim:
19. The method of any of claims 12-17, wherein the mammal has been infected with FMDV and the immune response is a therapeutic immune response.
- Claim:
20. A method of diagnosing a mammals infected with FMDV in mammal vaccinated with a vaccine of claim 8, the method comprising: a) isolating a fluid sample from the mammal; and b) detecting the presence of FMDV proteins not included in said vaccine and/or antibodies against FMDV proteins not included in said vaccine, wherein the presence of FMDV proteins not included in said vaccine and/or antibodies against FMDV proteins not included in said vaccine indicates the mammal has been infected with FMDV.
- Current International Class:
07; 61; 61; 61; 61; 61; 61; 12; 01
- الرقم المعرف:
edspap.20240360182
Processing Request
No Comments.